|Headquarters||Krka, d. d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenia|
|Number of employees||10,001+ employees|
Krka is one of the world’s leading generic pharmaceutical companies. Its medicines are used to treat more than 45 million patients every day in over 70 markets. The company's focus is on the development of high-quality own-brand generic pharmaceuticals, which offer added value, and are marketed under Krka's own brands. By making decisive moves, Krka has developed into an international pharmaceutical business group with more than 12,000 employees. With stable sales growth, investments, several development projects and good results, it has grown into a group that, in addition to the controlling company in Slovenia, also comprises several subsidiaries and representative companies in over 40 countries.
Krka has registered a wide range of products in different countries. There are differences in registration and availability of our products among the countries Prescription pharmaceuticals Krka has been granted marketing authorizations for a wide range of products in different countries. Non-prescription products Krka has a valuable range of high-quality non-prescription products, which covers the most important areas of self-medication. By constant upgrading of our portfolio with new products or line-extensions we stay in line with the needs and expectations of our customers and thus contribute to their health-related quality of life. Animal health products Krka’s modern animal health products provide effective and simple management of the most important bacterial infections, parasitic diseases and pain control.
Krka is successfully taking care of people’s health all around the world for over 60 years. The story of Krka began in 1954 when Boris Andrijanič established the Krka Pharmaceutical Laboratory in Novo Mesto. 1954–1964 Krka Pharmaceutical Laboratory was established Krka Production Plant was established the first patent was registered Krka re-locates to Ločna where a major part of production still occurs today Establishment of the Development Institute First cosmetic products launched First export ventures 1965–1974 Construction of the new plant for manufacturing active ingredients Extension of a new plant for manufacturing tablets and coated tablets Construction of a new plant for producing ointments, syrups, and injections Collection and processing of medicinal herbs Expansion to tourist and spa services Presentation of the first Krka Awards
1975–1984 registration granted by the American FDA for the manufacture of antibiotics the Dawa Pharmaceutical production plants began operation in Kenya fermentation capacities were increased by 50 % construction of a plant for converting pharmaceutical active ingredients into finished products investment in the preservation of clean waters and environment protection construction of the factory in Ljutomer investment in tourist/health-resort facilities
1985–1994 construction of a plant producing insulation material building marketing network abroad (establishment of companies and representative offices) accelerated development of Krka’s own generic drugs, and continued cooperation with the leading international pharmaceutical companies ranking in the top Slovene companies and exporters modernization of fermentation production ensuring a highly qualified professional workforce through the project of staff development increased investment in research and development
1995–2000 top-place ranking among pharmaceutical companies in Central and Eastern Europe, and penetration into Western European markets investment in research and development activities upgrading the Total Quality Management system restructuring into a joint-stock company
2001–2005 completion of the construction of the modern plant Notol for the production of solid dosage at the central Krka location expansion of production-distribution network abroad (new production-distribution plants in Poland, the Russian Federation and in Croatia) a new plant for the production of solid dosage forms in Šentjernej expansion of marketing and sales network Development and Control Centre 2 Acquisition of ISO 14001 standard (new quality in environment protection) Implementation of the new SAP information system Acquisition of the foodstuff safety system certificate (HACCP), safety and health at work (OHSAS 18001) and the certificate by the European Agency for Safety and Health at Work (EU-OSHA) Construction of the plant for the production of active pharmaceutical ingredients Synthesis 4
2006–2010 Expansion of the marketing and sales network Opening of Sinteza 4 API plant Introduction of no-par value shares (1:10 share split) Acquisition of ISO/IEC 27001 certificate for the information security system Highest national award for quality – the Business Excellence Award of the Republic of Slovenia (PRSPO) for 2007. Opening of the new injection production plant A new business center for warehousing products, customs operations and marketing activities in Macedonia Entry into a private Chinese pharmaceutical and chemical companies Zhejiang Menova Pharmaceuticals Co., Ltd., Shanghai and Anhua Menova Pharmaceuticals Co., Ltd., Purchase of German company TAD Pharma GmbH from Cuxhavna and Austrian company Alternova Arzneimittel GmbH from Vienna New chemical development laboratories
2011–2015 Opening of a state-of-the-art syrup production plant Opening of a state-of-the-art plant for the production of products with biocidal effect Starting the solar power plant Renovation and enlargement of a high bay warehouse for packaging material Opening of a state-of-the-art solid dosage forms production plant Opening of development and control centre RKC 3 Listing of Krka's shares on the Warsaw Stock Exchange Founding the company Farma GRS, d. o. o., together with partners within the pharmaceutical industry development project and building development and research, and production capacities Opening of the Krka-Rus 2 plant in the Russian Federation Opening of the plant for the production of active pharmaceutical ingredients Sinteza 1 in Krško Opening of the largest investment in Krka's history – a plant for the production of solid dosage forms Notol 2 with an annual production capacity of 4.5 billion of finished products Opening of a plant for the new generation lozenges in Ljutomer Strengthening the marketing and sales network comprising 28 subsidiaries and 19 representative offices together with production and distribution companies.